The combination of plasma glutamate and physical impairment after acute stroke as a potential indicator for the early-onset post-stroke depression

Geng, Leiyu; Qian, Fangyuan; Qian, Junfeng; Zhang, Zhijun

doi:10.1016/j.jpsychores.2017.01.006

Cited by 17 publications

(11 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, reduced DA concentrations in ischemic striatum have been demonstrated in a mouse model of chronic PSD [ 21 ]. In addition to monoamine neurotransmitters, a low plasma glutamate has also been reported to be associated with early-onset PSD recently [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Predictors of early-onset post-ischemic stroke depression: a cross-sectional study

Meng

et al. 2017

BMC Neurol

View full text Add to dashboard Cite

BackgroundPost-stroke depression (PSD) seriously affects the rehabilitation of nerve function and quality of life. However, the pathogenesis of PSD is still not clear. This study aimed to investigate the demographic, clinical, and biochemical factors in patients with PSD.MethodsPatients with an acute ischemic stroke, who met the inclusion criteria at Shanghai Tenth People’s Hospital from April 2016 to September 2016, were recruited for this study. The stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS), and the mental state was assessed using Mini-Mental State Examination (MMSE), Hamilton Depression Scale (HAMD), and Hamilton Anxiety Scale (HAMA) at 1 week of admission. The patients were divided into PSD and non-PSD groups. The demographic and clinical characteristics, as well as the biochemical factors, were compared between the two groups. A logistic regression analysis was performed to identify the risk factors for depression following stroke.ResultsA total of 83 patients with acute ischemic stroke were recruited. Of these, 36 (43.4%) developed depression. The multivariate logistic regression analysis indicated that high NIHSS [odds ratio (OR): 1.84, 95% confidence interval (CI): 1.09–3.12, P = 0.023] and high HAMD scores (OR: 2.38, 95% CI: 1.61–3.50, P < 0.001) were independent risk predictors for PSD and so were lower dopamine level (OR: 0.64, 95% CI: 0.45–0.91, P = 0.014), lower 5-hydroxytryptamine level (OR: 0.99, 95% CI: 0.98–1.00, P = 0.046), higher tumor necrosis factor-α level (OR: 1.05, 95% CI: 1.00–1.09, P = 0.044), and lower nerve growth factor level (OR: 0.06, 95% CI: 0.01–0.67, P = 0.022).ConclusionsThe identification of higher NIHSS scores, higher HAMD scores, lower dopamine level, lower 5-hydroxytryptamine level, higher tumor necrosis factor-α level, and lower nerve growth factor level might be useful for clinicians in recognizing and treating depression in patients after a stroke.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of early-onset post-ischemic stroke depression: a cross-sectional study

Meng

et al. 2017

BMC Neurol

View full text Add to dashboard Cite

show abstract

“…17-item Hamilton Depression Rating Scale(HAMD-17) was examined for all subjects [ 12 ]. The severity of depressive symptom was classified by the following severity range for HAMD-17 score: mild depression (8–17), moderate depression (18–24), and severe depression (> 24) [ 13 ].…”

Section: Methodsmentioning

confidence: 99%

Plasma nesfatin-1 level is associated with severity of depression in Chinese depressive patients

Xiao

Jiang

et al. 2018

BMC Psychiatry

View full text Add to dashboard Cite

BackgroundNesfatin-1 plays a role in the regulation of emotional states like depression. The aim of this study was to investigate the plasma nesfatin-1levels in Chinese patients with depression and healthy subjects, and to determine the possible association between the plasma nesfatin-1 level and the severity of depression.MethodsA total of 103 depressive patients and 32 healthy subjects were assessed. According to HAMD-17scores, 51, 18, and 34 patients were enrolled in the mild depression, moderate depression, and severe depression groups, respectively. Plasma nesfatin-1 levels were determined by the ELISA method. Differences between groups were compared and associations between plasma nesfatin-1 and other variables were analyzed.ResultsThe plasma nesfatin-1 was significantly positively correlated with HAMD-17 score (r = 0.651). Compared with healthy controls (8.11 ± 3.31 ng/mL), the plasma nesfatin-1 level significantly increased in patients with mild depression (11.17 ± 3.58 ng/mL), with moderate depression (16.33 ± 8.78 ng/mL), and with severe depression (27.65 ± 8.26 ng/mL) respectively. Plasma nesfatin-1 level (Odds ratio [OR] = 1.269) was an independent indicator for severe depression by multivariate logistic regression analysis.ConclusionThe plasma nesfatin-1 level is positively correlated with the severity of depression. Plasma nesfatin-1 level may be a potential indicator for depression severity.

show abstract

“…[66] Similarly, reduced dopamine concentrations in ischemic striatum have been demonstrated in a mouse model of chronic PSD. [74] In addition to monoamine neurotransmitters, a low plasma glutamate has also been reported to be associated with early-onset PSD. This study found that the levels of IL-6 and TNF-α significantly higher in the PSD group than in the non-PSD group.…”

Section: Vinpocetine and Postischemic Stroke Immunological And Inflammentioning

confidence: 99%

Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review

et al. 2020

View full text Add to dashboard Cite

Vinpocetine (VPN) is a synthetic ethyl-ester derivative of the alkaloid apovincamine from Vinca minor leaves. VPN is a selective inhibitor of phosphodiesterase type 1 (PDE1) that has potential neurological effects through inhibition of voltage-gated sodium channel and reduction of neuronal calcium influx. VPN has noteworthy antioxidant, anti-inflammatory, and anti-apoptotic effects with inhibitory effect on glial and astrocyte cells during and following ischemic stroke (IS). VPN is effective as adjuvant therapy in the management of epilepsy; it reduces seizure frequency by 50% in a dose of 2 mg/kg/day. VPN improves psychomotor performances through modulation of brain monoamine pathway mainly on dopamine and serotonin, which play an integral role in attenuation of depressive symptoms. VPN recover cognitive functions and spatial memory through inhibition of hippocampal and cortical PDE1 with augmentation of cyclic adenosin monophosphate and cyclic guanosin monophosphate ratio, enhancement of cholinergic neurotransmission, and inhibition of neuronal inflammatory mediators. Therefore, VPN is an effective agent in the management of IS and plays an integral role in the prevention and attenuation of poststroke epilepsy, depression, and cognitive deficit through direct cAMP/cGMP-dependent pathway or indirectly through anti-inflammatory and antioxidant effects.

show abstract

The combination of plasma glutamate and physical impairment after acute stroke as a potential indicator for the early-onset post-stroke depression

Cited by 17 publications

References 67 publications

Predictors of early-onset post-ischemic stroke depression: a cross-sectional study

Predictors of early-onset post-ischemic stroke depression: a cross-sectional study

Plasma nesfatin-1 level is associated with severity of depression in Chinese depressive patients

Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review

Contact Info

Product

Resources

About